Woodland Hills, CA, United States of America

David Gordon Bermudes

This inventor holds 61 USPTO granted patents and 1 published patent application, plus 2 CIPO patents, primarily in Therapeutic Bacteria (CPC class A61K). Top assignees: Vion Pharmaceuticals, Inc., Aviex Technologies LLC, Yale University. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Gordon Bermudes. Retrieved from https://idiyas.com/inventor/david-gordon-bermudes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 61 

% Patents Active = 59.0


Average Co-Inventor Count = 1.2

ph-index = 22

Forward Citations = 1,278(Granted Patents)

Forward Citations (Not Self Cited) = 459(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Wallingford, CT (US) (2000 - 2009)
  • Kenwood, CA (US) (2012 - 2019)
  • Woodland Hills, CA (US) (2014 - 2023)

Company Filing History:


Years Active: 2000-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Therapeutic Proteins
Tumor Colonization
Protease Inhibitors
Chimeric Peptides
Immunotherapy
Bacterial Vectors
Copper Chelation
Live Vaccines
SARS-CoV-2
Bacteriophage
Cytotoxic Toxins
Antibody Combinations
61 patents (USPTO):Explore Patents

Title: **David Gordon Bermudes: A Pioneer in Therapeutic Innovations**

Introduction

David Gordon Bermudes, located in Woodland Hills, CA, has made significant strides in the field of biotechnology and therapeutics. With a remarkable portfolio of 57 patents, Bermudes is recognized for his innovative approaches to addressing complex medical challenges, particularly in relation to copper-related diseases and inflammatory disorders.

Latest Patents

Among his most recent contributions to the scientific community is the patent titled "Copper chelation therapeutics." This invention involves bacterial strains engineered to sequester and neutralize copper ions as well as toxic divalent transition metals. The therapeutic potential of these bacteria includes reducing the availability of copper to cancerous tissues, thereby inhibiting tumor growth, angiogenesis, and metastasis. Furthermore, this approach shows promise in the treatment of various neoplastic diseases like solid tumors, lymphomas, Wilson's Disease, Menke's Disease, and has potential implications for Alzheimer's Disease, Parkinson's Disease, and Creutzfeldt-Jakob Disease.

Another significant patent by Bermudes focuses on "Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment." This invention highlights the co-expression of protease inhibitors with therapeutic agents, including phage that deliver peptides, antibodies, and nucleic acid-based therapeutics. The application of this technology is broad, targeting inflammation related to disorders such as psoriasis, atopic dermatitis, and inflammatory bowel disease, while also addressing the inhibition of intestinal parasites.

Career Highlights

Throughout his career, Bermudes has held positions in significant companies, including Vion Pharmaceuticals, Inc. His work in these organizations has allowed him to develop innovative therapeutic methods, contributing to advancements in the medical field.

Collaborations

David Bermudes has collaborated with notable professionals in the industry, including Kenneth Brooks Low and David Quintero. These partnerships have likely facilitated the exchange of ideas and have been crucial for the development and refinement of his groundbreaking patents.

Conclusion

David Gordon Bermudes exemplifies the spirit of innovation through his extensive work in developing advanced therapeutic strategies. His contributions not only enhance our understanding of complex medical conditions but also pave the way for future research and treatment options in biotechnology, establishing him as a key figure in the realm of therapeutic inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…